Skip Nav Destination
Issues
1 January 2007
-
Cover Image
Cover Image
SMAD4 is a tumor suppressor gene whose inactivation by the various mechanisms frequently occurs in association with malignant progression. Cytoplasmic and nuclear expression levels of SMAD4 are increased in both low-grade and high-grade dysplasia but are gradually reduced as dysplasia progresses to gastric adenocarcinoma. This figure shows strong cytoplasmic and nuclear staining of SMAD4 in stage I of gastric carcinoma, but SMAD4 is gradually reduced as the carcinoma develops to subsequent stages, possibly owing to a modified two-hit model of tumor suppressor genes as proposed in the article. For more details, please see Wang et al. on page 102 of this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
The Biology Behind
Molecular Pathways
Review
Human Cancer Biology
Ubiquitin COOH-Terminal Hydrolase 1: A Biomarker of Renal Cell Carcinoma Associated with Enhanced Tumor Cell Proliferation and Migration[?Q1: Running head: UCHL1, a Biomarker of RCC. Short title OK?Q1]
Barbara Seliger; Alla Fedorushchenko; Walburgis Brenner; Angelika Ackermann; Derek Atkins; Samir Hanash; Rudolf Lichtenfels
Radiation Effects on Development of HER2-Positive Breast Carcinomas
Fabio Castiglioni; Monica Terenziani; Maria Luisa Carcangiu; Raffaella Miliano; Piera Aiello; Lorenzo Bertola; Tiziana Triulzi; Patrizia Gasparini; Tiziana Camerini; Gabriella Sozzi; Franca Fossati-Bellani; Sylvie Ménard; Elda Tagliabue
Determination of Microvessel Density by Quantitative Real-time PCR in Esophageal Cancer: Correlation with Histologic Methods, Angiogenic Growth Factor Expression, and Lymph Node Metastasis
Sonja Loges; Henning Clausen; Uta Reichelt; Michael Bubenheim; Andreas Erbersdobler; Paulus Schurr; Emre Yekebas; Gunter Schuch; Jakob Izbicki; Klaus Pantel; Carsten Bokemeyer; Walter Fiedler
Caveolin 1 Is Overexpressed and Amplified in a Subset of Basal-like and Metaplastic Breast Carcinomas: A Morphologic, Ultrastructural, Immunohistochemical, and In situ Hybridization Analysis
Kay Savage; Maryou B.K. Lambros; David Robertson; Robin L. Jones; Chris Jones; Alan Mackay; Michelle James; Jason L. Hornick; Emilio M. Pereira; Fernanda Milanezi; Christopher D.M. Fletcher; Fernando C. Schmitt; Alan Ashworth; Jorge S. Reis-Filho
Imaging, Diagnosis, Prognosis
Pathologic and Molecular Heterogeneity in Imatinib-Stable or Imatinib-Responsive Gastrointestinal Stromal Tumors
Narasimhan P. Agaram; Peter Besmer; Grace C. Wong; Tianhua Guo; Nicholas D. Socci; Robert G. Maki; Diann DeSantis; Murray F. Brennan; Samuel Singer; Ronald P. DeMatteo; Cristina R. Antonescu
Risk of Second Cancer in Nongastric Marginal Zone B-Cell Lymphomas of Mucosa-Associated Lymphoid Tissue: A Population-Based Study from Northern Italy
Luca Arcaini; Sara Burcheri; Andrea Rossi; Cristiana Pascutto; Francesco Passamonti; Ercole Brusamolino; Marco Paulli; Ester Orlandi; Maurizio Buelli; Piera Viero; Marco Lucioni; Francesca Montanari; Michele Merli; Sergio Cortelazzo; Mario Lazzarino
Nonsynonymous Coding Single-Nucleotide Polymorphisms Spanning the Genome in Relation to Glioblastoma Survival and Age at Diagnosis
Margaret Wrensch; Alex McMillan; John Wiencke; Joe Wiemels; Karl Kelsey; Joe Patoka; Hywel Jones; Victoria Carlton; Rei Miike; Jennette Sison; Michelle Moghadassi; Michael Prados
Cancer Therapy: Clinical
Expression of Cellular FLICE Inhibitory Protein, Caspase-8, and Protease Inhibitor-9 in Ewing Sarcoma and Implications for Susceptibility to Cytotoxic Pathways
Alfons S.K. de Hooge; Dagmar Berghuis; Susy Justo Santos; Esther Mooiman; Salvatore Romeo; J. Alain Kummer; R. Maarten Egeler; Maarten J.D. van Tol; Cornelis J.M. Melief; Pancras C.W. Hogendoorn; Arjan C. Lankester
Increased Dose Density Is Feasible: A Pilot Study of Adjuvant Epirubicin and Cyclophosphamide followed by Paclitaxel, at 10- or 11-Day Intervals with Filgrastim Support in Women with Breast Cancer
Monica N. Fornier; Andrew D. Seidman; Diana Lake; Gabriella D'Andrea; Jacqueline Bromberg; Mark Robson; Catherine Van Poznak; Katherine S. Panageas; Marietta Atienza; Larry Norton; Clifford Hudis
Neoadjuvant Therapy with Paclitaxel followed by 5-Fluorouracil, Epirubicin, and Cyclophosphamide Chemotherapy and Concurrent Trastuzumab in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: An Update of the Initial Randomized Study Population and Data of Additional Patients Treated with the Same Regimen
Aman U. Buzdar; Vicente Valero; Nuhad K. Ibrahim; Deborah Francis; Kristine R. Broglio; Richard L. Theriault; Lajos Pusztai; Marjorie C. Green; Sonja E. Singletary; Kelly K. Hunt; Aysegul A. Sahin; Francisco Esteva; William F. Symmans; Michael S. Ewer; Thomas A. Buchholz; Gabriel N. Hortobagyi
Cancer Therapy: Preclinical
The Combi-Targeting Concept: In vitro and In vivo Fragmentation of a Stable Combi-Nitrosourea Engineered to Interact with the Epidermal Growth Factor Receptor while Remaining DNA Reactive
Qiyu Qiu; Juozas Domarkas; Ranjita Banerjee; Nuria Merayo; Fouad Brahimi; James P. McNamee; Bernard F. Gibbs; Bertrand J. Jean-Claude
Cancer Susceptibility and Prevention
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds